Minerva Neurosciences (NASDAQ:NERV) Earns Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $8.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Minerva Neurosciences’ FY2027 earnings at ($1.86) EPS.

Separately, StockNews.com upgraded Minerva Neurosciences from a sell rating to a hold rating in a research report on Tuesday, March 7th.

Minerva Neurosciences Trading Down 8.0 %

NASDAQ NERV opened at $1.67 on Thursday. The business’s 50 day moving average is $2.18 and its two-hundred day moving average is $4.56. Minerva Neurosciences has a 12-month low of $1.26 and a 12-month high of $15.27. The stock has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.28 and a beta of 0.07.

Institutional Investors Weigh In On Minerva Neurosciences

Several institutional investors have recently modified their holdings of NERV. Renaissance Technologies LLC boosted its stake in shares of Minerva Neurosciences by 185.9% during the 3rd quarter. Renaissance Technologies LLC now owns 101,800 shares of the biopharmaceutical company’s stock worth $940,000 after acquiring an additional 66,189 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Minerva Neurosciences by 54.7% during the 3rd quarter. BlackRock Inc. now owns 78,086 shares of the biopharmaceutical company’s stock worth $721,000 after acquiring an additional 27,612 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Minerva Neurosciences in the 3rd quarter valued at approximately $231,000. Truist Financial Corp purchased a new stake in Minerva Neurosciences in the 3rd quarter valued at approximately $102,000. Finally, UBS Group AG lifted its stake in Minerva Neurosciences by 914.5% in the 3rd quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 5,167 shares in the last quarter. Hedge funds and other institutional investors own 38.00% of the company’s stock.

Minerva Neurosciences Company Profile

(Get Rating)

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.